August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
January 2026 in “Figshare” January 2026 in “Figshare” March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” Early diagnosis, genetic testing, and personalized care are essential for managing tuberous sclerosis.
March 2026 in “Mendeley Data” rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
February 2009 in “Journal of The American Academy of Dermatology” Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
March 2026 in “Pharmaceuticals” Reporter characteristics affect detection of hair loss from cancer therapy.
1 citations
,
January 2016 in “Journal of Clinical & Experimental Dermatology Research”
A 72-year-old man was diagnosed with a rare skin form of Rosai-Dorfman disease after years of misdiagnosis.
Trichoscopy is effective for tracking treatment progress in hair loss when used by an experienced doctor.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
OCT can effectively diagnose different stages of hair loss non-invasively.
12 citations
,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
December 2012 in “http://isrctn.org/>”
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
December 2025 in “Journal of Dermatological Treatment” GT20029 helps regrow hair in men with hair loss and is well-tolerated.
The treatment was not recommended due to limited effectiveness and significant side effects.
September 2017 in “Pure and Applied Biology” Chemotherapy and radiotherapy improved quality of life and reduced symptoms in lung cancer patients.
November 2019 in “Neuro-oncology” Rind-based techniques can lower scalp radiation dose and reduce hair loss in brain cancer treatment.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
1 citations
,
February 2018 in “Orthopedics and rheumatology” Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
4 citations
,
August 2019 in “Actas Dermo-Sifiliográficas” The Spanish HSS-29 scale effectively measures changes in life quality due to female-pattern hair loss.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.